Brenus Pharma

Brenus Pharma is a French biotechnology company focused on developing innovative cancer immunotherapies, particularly through its proprietary Stimulated Tumor Cell (STC) platform. The company's approach aims to address unmet needs in the treatment of solid tumors by leveraging allogeneic cell-based vaccines that stimulate the immune system to recognize and attack cancer cells, even as they evolve. Their flagship product, STC-1010, is designed to target colorectal cancer, which is among the leading causes of cancer-related deaths worldwide​

​

.

The core of Brenus Pharma’s technology lies in its STC platform, which aims to improve the immunogenicity and antigenicity of tumor cells used in vaccines. This approach educates the patient’s immune system to detect a wide range of tumor antigens, thereby enhancing the body's ability to fight cancer over time. Unlike traditional therapies that may lose effectiveness as tumors mutate, Brenus’s method adapts to the changing nature of cancer cells, making it a promising candidate for treating different types of solid tumors​

.

Brenus Pharma's STC-1010 has shown encouraging preclinical results, including studies on various models of colorectal cancer. These studies have demonstrated consistency in immune response with the STC platform, suggesting its potential for broader application in clinical trials. The company's research has been presented at several prominent scientific gatherings, such as the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO)​

.

Moreover, Brenus Pharma is positioning its STC-based therapies as a first-line treatment option that can be used in combination with other standard treatments. This strategy aims to create synergistic effects with existing immunotherapies, rather than directly competing with them. This approach could extend the availability of innovative treatments to a larger patient population, offering a new avenue in the evolving landscape of cancer immunotherapy​

.

The company is backed by an experienced team with expertise in biotechnology, clinical research, and the regulatory landscape, which has helped it navigate complex preclinical and regulatory processes. Brenus has completed preclinical packages that have been endorsed by key regulatory bodies like the FDA and FAMHP (European Medicines Agency). This milestone positions Brenus for upcoming Phase I/II clinical trials, aimed at further assessing the efficacy and safety of STC-1010 in patients​

.

Through its innovative platform and promising early-stage results, Brenus Pharma aims to shift the paradigm in cancer treatment, providing new hope for patients facing challenging forms of cancer. With a commitment to leveraging cutting-edge immunotherapy approaches, Brenus is working toward the commercialization of treatments that could significantly impact the field of oncology and improve outcomes for patients​

.